Kamata K, Satoh T, Matsumoto T, Noguchi E, Taguchi K, Kobayashi T, Tanaka H, Shigenobu K
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Tokyo, Japan.
Acta Physiol (Oxf). 2006 Nov-Dec;188(3-4):173-83. doi: 10.1111/j.1748-1716.2006.01616.x.
To clarify the time-related changes in cardiac function and the mechanism underlying the cardiac dysfunction present in diabetes mellitus, we studied mechanical responses induced by alpha(1)- and beta-adrenoceptors, the Ca(2+)-entry promoter Bay K 8644- and ryanodine (an agent known to inhibit Ca(2+) release from the sarcoplasmic reticulum) in papillary muscles from streptozotocin (STZ)-induced diabetic and age-matched control rats.
Male Wistar rats received a single injection of STZ (60 mg kg(-1)) via the tail vein to induce diabetes. For the mechanical studies, papillary muscle preparations were suspended in an organ bath and isometric contractions were measured in 1-, 4-, and 10-week STZ-induced diabetic and age-matched control rats.
In 1-week diabetic rats, the contractions induced by isoproterenol, methoxamine and Bay K 8644 were unchanged (vs. age-matched controls). In 4-week diabetic rats, (a) the isoproterenol- and Bay K 8644-induced contractions were impaired, (b) sensitivity to ryanodine was reduced, whereas (c) the methoxamine-induced contraction was unchanged. In 10-week diabetic rats, the isoproterenol- and Bay K 8644-induced contractile responses were impaired and the sensitivity to ryanodine was reduced, but in sharp contrast the methoxamine-induced contraction was enhanced. Both the mRNA level for the alpha(1A) adrenoceptor (but not the alpha(1B) or alpha(1D) mRNAs) and alpha(1A) adrenoceptor protein were increased in 10-week diabetic rats (vs. age-matched controls).
These results suggest that impairments of beta-adrenergic and Ca(2+)-handling mechanisms occur early in the development of cardiomyopathy in STZ-induced diabetic rats, and that this is followed by augmentation of alpha(1A) adrenoceptor-mediated inotropy due to alpha(1A) adrenoceptor upregulation.
为了阐明糖尿病患者心脏功能随时间的变化以及心脏功能障碍的潜在机制,我们研究了链脲佐菌素(STZ)诱导的糖尿病大鼠和年龄匹配的对照大鼠乳头肌中α(1)-和β-肾上腺素能受体、钙内流促进剂Bay K 8644以及ryanodine(一种已知可抑制肌浆网释放钙的药物)所诱导的机械反应。
雄性Wistar大鼠经尾静脉单次注射STZ(60 mg kg(-1))以诱导糖尿病。为进行机械研究,将乳头肌标本悬于器官浴槽中,测量1周、4周和10周STZ诱导的糖尿病大鼠及年龄匹配的对照大鼠的等长收缩。
在1周龄糖尿病大鼠中,异丙肾上腺素、甲氧明和Bay K 8644所诱导的收缩无变化(与年龄匹配的对照相比)。在4周龄糖尿病大鼠中,(a)异丙肾上腺素和Bay K 8644所诱导的收缩受损,(b)对ryanodine的敏感性降低,而(c)甲氧明所诱导的收缩无变化。在10周龄糖尿病大鼠中,异丙肾上腺素和Bay K 8644所诱导的收缩反应受损,对ryanodine的敏感性降低,但与之形成鲜明对比的是,甲氧明所诱导的收缩增强。在10周龄糖尿病大鼠中,α(1A)肾上腺素能受体的mRNA水平(而非α(1B)或α(1D) mRNA)和α(1A)肾上腺素能受体蛋白均增加(与年龄匹配的对照相比)。
这些结果表明,在STZ诱导的糖尿病大鼠心肌病发展早期,β-肾上腺素能和钙处理机制受损,随后由于α(1A)肾上腺素能受体上调,α(1A)肾上腺素能受体介导的心肌收缩力增强。